As the nationwide Adderall shortage rolls on, two more companies are joining the long list of suppliers struggling to meet demand.
Lannett Co. and Par Pharmaceuticals joined Teva, Amneal Pharmaceuticals, Rhodes Pharmaceuticals, Sandoz and more on the list of companies experiencing shortages of the attention-deficit and hyperactivity disorder drug. Some patients who take daily medication are being told that the pill is out of stock at pharmacies, according to reports.
In an update, the American Society of Health-System Pharmacists (ASHP) listed Lannett's extended release, 100-count bottles of the drug at the 15-mg dose as affected by the nationwide shortage. Par's 100-count bottles of the drug at 20-mg and 30-mg doses are also affected, according to the ASHP.
The shortage started back in early August when generic drug giant Teva began struggling to meet demand. Shortly after, Amneal, Rhodes and Sandoz were involved in the nationwide shortfall.
An unprecedented spike in Adderall prescriptions has prompted the supply issues. Previously, Bloomberg attributed the spike in prescriptions to a combination of increased diagnoses and greater availability of the medicine through online startups.
Par and Lannett did not reply to Fierce Pharma’s request for comment at the time of publication.